The TET2 variant was also observed in the bone marrow aspirate at the time of AML-pCT diagnosis, and both variants were detected in a surveillance ctDNA sample 12 months after AML-pCT diagnosis, with additional variants in TET2 and KRAS (Supplementary Table S1). This evidence concerns the gene KRAS and acute myeloid leukemia.